Stay updated on Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab
Sign up to get notified when there's something new on the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page.

Latest updates to the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe Publications section now states that items are automatically filled from PubMed and may not be about the study. Revision tag updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check27 days agoChange DetectedA notice about government funding-related delays and operating status was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check49 days agoChange DetectedResults section has been added, including primary and secondary outcomes (ORR, DCR, DoR, PFS, OS) and updated study dates reflecting posted results.SummaryDifference0.4%

- Check70 days agoChange DetectedSummary: The page now displays a funding-status notice and updates the version to v3.2.0, replacing v3.1.0.SummaryDifference2%

- Check77 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0, indicating a newer release.SummaryDifference0.1%

- Check92 days agoChange DetectedUpgrade to v3.0.2 from v3.0.1; removal of the 'Back to Top' element and no changes to core content.SummaryDifference0.1%

Stay in the know with updates to Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab
Enter your email address, and we'll notify you when there's something new on the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page.